Shipra Gandhi, MD Shipra Gandhi, MD

Shipra Gandhi

MD
Medical Oncology
About Shipra Gandhi

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Breast and Early Phase Clinical Trials, Department of Medicine

Background

Education and Training:

  • 2010 - MD - Lady Hardinge Medical College, Delhi, India

Residency:

  • 2012-2015 - Internal Medicine, State University of New York at Buffalo, Buffalo, NY

Fellowship:

  • 2015-2018 - Hematology-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Board Certification:

  • Hematology and Oncology - American Board of Internal Medicine
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Learn More
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Learn More
Evaluate Eribulin ORA in Subjects With Solid Tumors
Learn More
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Learn More
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Learn More
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Learn More
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
Learn More

Clinical Trials

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Learn More
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Learn More
Evaluate Eribulin ORA in Subjects With Solid Tumors
Learn More
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Learn More
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Learn More
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Learn More
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
Learn More

Publications

Full Publications list on PubMed

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment